DDInter1458 DDInter1376
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Phenylpropanolamine {u} (Compound) resembles {v} (Compound) Metaraminol
Phenylpropanolamine {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amphetamine
Phenylpropanolamine {u} (Compound) treats {v} (Disease) obesity
Phenylpropanolamine {u} (Compound) binds {v} (Gene) ADRB2
Phenylpropanolamine {u} (Compound) upregulates {v} (Gene) HBB
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) PRR7
Phenylpropanolamine {u} (Compound) causes {v} (Side Effect) Ataxia
Phenylpropanolamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Colchicine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Phenylpropanolamine (Compound) resembles Metaraminol (Compound)
Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine
Phenylpropanolamine (Compound) treats obesity (Disease)
Phenylpropanolamine (Compound) binds ADRB2 (Gene)
Phenylpropanolamine (Compound) upregulates HBB (Gene)
Phenylpropanolamine (Compound) downregulates PRR7 (Gene)
Phenylpropanolamine (Compound) causes Ataxia (Side Effect)
Phenylpropanolamine may cause a minor interaction that can limit clinical effects when taken with Colchicine
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine